Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 2 |
2023 | 5 |
2024 | 1 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
T/myeloid MPAL with biallelic CEBPA mutations.
Blood. 2023 Oct 26;142(17):1500. doi: 10.1182/blood.2023021647.
Blood. 2023.
PMID: 37883109
No abstract available.
Impact of secondary-type mutations in NPM1 mutated AML.
Zhou Q, Zhao D, Zarif M, Yeung YWT, Richard-Carpentier G, Chang H.
Zhou Q, et al. Among authors: zarif m.
Eur J Haematol. 2023 Jul;111(1):165-168. doi: 10.1111/ejh.13979. Epub 2023 May 10.
Eur J Haematol. 2023.
PMID: 37165755
No abstract available.
Item in Clipboard
TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation.
Zhao D, Zarif M, Zhou Q, Capo-Chichi JM, Schuh A, Minden MD, Atenafu EG, Kumar R, Chang H.
Zhao D, et al. Among authors: zarif m.
Cancers (Basel). 2023 Jun 16;15(12):3210. doi: 10.3390/cancers15123210.
Cancers (Basel). 2023.
PMID: 37370821
Free PMC article.
Item in Clipboard
NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
Zhao D, Zarif M, Eladl E, Capo-Chichi JM, Smith AC, Atenafu EG, Tierens A, Minden MD, Schuh A, Chang H.
Zhao D, et al. Among authors: zarif m.
Leuk Res. 2022 Jul;118:106869. doi: 10.1016/j.leukres.2022.106869. Epub 2022 May 22.
Leuk Res. 2022.
PMID: 35636054
Item in Clipboard
Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
Zhao D, Eladl E, Zarif M, Capo-Chichi JM, Schuh A, Atenafu E, Minden M, Chang H.
Zhao D, et al. Among authors: zarif m.
Cancer Med. 2023 Mar;12(6):6511-6522. doi: 10.1002/cam4.5421. Epub 2022 Nov 16.
Cancer Med. 2023.
PMID: 36394085
Free PMC article.
Item in Clipboard
AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.
Zhao D, Zhou Q, Zarif M, Eladl E, Wei C, Atenafu EG, Schuh A, Tierens A, Yeung YWT, Minden MD, Chang H.
Zhao D, et al. Among authors: zarif m.
Leuk Res. 2023 Nov;134:107376. doi: 10.1016/j.leukres.2023.107376. Epub 2023 Aug 29.
Leuk Res. 2023.
PMID: 37690321
Item in Clipboard
A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.
Zhou Q, Zhao D, Zarif M, Davidson MB, Minden MD, Tierens A, Yeung YWT, Wei C, Chang H.
Zhou Q, et al. Among authors: zarif m.
Blood Adv. 2024 Apr 9;8(7):1760-1771. doi: 10.1182/bloodadvances.2023011869.
Blood Adv. 2024.
PMID: 38286462
Free PMC article.
Item in Clipboard
Cite
Cite